Search
Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16917ApprovedInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
EpiVacCorona
go.drugbank.com/drugs/DB16439InvestigationalIt is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613]. … EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608].
Verubulin
go.drugbank.com/drugs/DB05585InvestigationalAntineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10598ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10599ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10601ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10773ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10791ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10794ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.